Jannat Nayem is a Senior Project Manager in the Office of Technology Development. She joined MSK in 2022 and leads antibody drug development activities within OTD.

Prior to MSK, she was a scientist in the drug product development department of Janssen where she led antibody-based drug development with strategic planning and execution of preclinical, clinical, and commercialization activities. Earlier, she was a scientist in the process development biologics department at Amgen where she led high concentration formulation development and developability assessments of biologics in the preclinical space.

Jannat received her PhD in Chemical Engineering in 2020 from the University of Delaware where she developed structure-property relationships of concentrated therapeutic antibody formulations. She received her Bachelor of Science degree in Chemical Engineering from the City College of New York in 2014.